BIOS LIFE CLINICAL STUDIES

EOT
No. Name Year Location Researchers N Design Intervention Outcomes Inclusion BL % % % vs Placebo
1 Cleveland 2001 Cleveland Dennis L. 99 DBPC 8 weeks
Clinic Clinic Sprecher,

Publications Active
Sprecher DL, Pearce GL (2002) Fiber-multivitamin combination therapy: a TC 237 227 -4.20% -5.90%
beneficial influence on low-density lipoprotein and homocysteine Metabolism LDL >130 159 145 -8.80% -12.00%
51, 1166-70. HDL 48 51 6.30% 0.00%
TG 146 119 -18.50% -5.60%
GLU 83 83 0.00% -3.70%
ApoB 139 110 -20.90% -20.90%
Hcy 9.8 8.7 -11.20% -9.10%
Weight 85 84 -1.20% -2.40%

Placebo
TC 242 246 1.70%
LDL >130 158 163 3.20%
HDL 48 51 6.30%
TG 140 122 -12.90%
GLU 82 85 3.70%
ApoB 135 135 0.00%
Hcy 9.4 9.2 -2.10%
Weight 80 81 1.30%

2 Phillipines 2003 Angeles Edwin B. 103 Open 4 weeks

University Balajadia, label
Foundation Amiel S
Medical Valerio,
Center, Norberto
Angeles Yumul
City,
Philippines
Publications
Balajadia E, Valerio A, Yumul N. Beneficial effects of Bios Life 2 (Dietary Fiber
Supplement) in patients with dyslipidemia. in 34th Annual Convention of the
Philippine College of Physicians. 2004. TC 267 222 -16.90%

1 OF 4
 BIOS LIFE CLINICAL STUDIES

EOT
No. Name Year Location Researchers N Design Intervention Outcomes Inclusion BL % % % vs Placebo
3 Diabetes 1999 Deerfield, IL Steven H. 15 Open 12 weeks
in control Freed, David label
#1 J. Joffe
Publications TC 210 -12%
Freed S, Joffe D (2000) The Clinical Impact of Fiber Supplementation for the HDL 35 37 6%
Reduction of Postprandial Blood Glucose and Risk Reduction of Complications TG 299 173 -42%
from Diabetes Diabetes in Control 12-8. GLU pre 150 125 -17%
GLU post 250 160 -36%
HbA1c 9.2 7.8 -15.20%
Weight 208 202 -2.90%

4 Diabetes 2004 Deerfield, IL Steven H. 78 Open 90 days

in control Freed, David label
#2 J. Joffe

Publications
TC 215 184 -14.40%
Freed S, Joffe D (2004) The Clinical Impact of Fiber Supplementation for the
Reduction of Postprandial Blood Glucose and Risk Reduction of Complications
LDL 129 92 -28.70%
from Diabetes II Diabetes in Control 212, 17. Verdegem P, Freed S, Joffe D.
The Clinical Impact of Fiber Supplementation on Cardio-Vascular Risk HDL 43 55 27.90%
Parameters in type-2 Diabetes. in 6th International Conference on
Atherosclerosis, Thrombosis and Verdegem P, Freed S, Joffe D (2005) The TG 299 257 -14.00%
clinical impact of fiber supplementation for the reduction of post-Vascular
Biology. 2005. Washinton, DC, USA Verdegem P, Freed S, Joffe D. The Clinical GLU pre 173 156 -9.80%
Impact of Fiber Supplementation for the Reduction of Post-prandial Blood
Glucose and Risk Reduction of Complications from Type-2 Diabetes. in 65th GLU post 278 237 -14.70%
Scientific Session American Diabetes Association. 2005. San Diego, CA, USA.
HbA1c 9 8.1 -10.00%
prandial blood blucose and reduction of complications from type-2 diabetes
Diabetes 54, A425. Weight 182 176 -3.30%

2 OF 4
 BIOS LIFE CLINICAL STUDIES

EOT
No. Name Year Location Researchers N Design Intervention Outcomes Inclusion BL % % % vs Placebo
5 Utah #1 2005 Orem, UT Peter J.E. 25 Open 8 weeks
Verdegem label

Publications TC 214 196 -8.20%

Verdegem P (2007) Viscous soluble fiber combined with phytosterols and > 200 237 211 -10.70%
policosanol reduces LDL-c and increases HDL-c in hypercholesterolemia Current LDL 131 111 -4.80%
Topics in Neutraceutical Research in press, > 130 168 127 -24.50%
> 160 182 127 -30.60%
HDL 48 52 8.30%
< 40 32 37 12.00%
TG 176 166 -5.70%
> 150 228 194 -14.90%
Ratio 4.89 4.14 -5.30%
> 5.0 6.51 5.04 -24.20%

6 Pacific 2005 The doctor's Vincent 24 Open 6 weeks

Rim clinic, Duenas, Julie label
Tamuning, Duenas,
GU Evelyn Burke,
Peter
Verdegem

Publications TC >200 235 232 -1.40%

Duenas V, Duenas J, Burke E, Verdegem P (2006) A new fiber drink provides a LDL >130 157 131 -16.10%
natural first line treatment option in mild hypercholesterolemia Arterioscler LDL >160 180 150 -16.60%
Thromb Vasc Biol 26, e53-e107. Duenas V, Duenas J, Burke E, Verdegem P. A HDL <40 35 45 27.90%
new fiber drink can serve as an adjunct therapy to statin medication in mild Risk ratio 5.1 4.3 -15.00%
hypercholesterolemia. in 7th Annual Conference on Arteriosclerosis, Thrombosis
and Vascular Biology. 2006. Denver. Verdegem P, Duenas V, Duenas J, Burke
E. LDL- and HLD-cholesterol optimization using phytonutrient combination TC >200 232 229 -1% Statin Users
therapy: first line intervention and adjunct therapy to statins. in 1st Asian
Preventive Cardiology & Cardiac Rehabilitation Conference. 2006. Hong Kong.
LDL >130 150 118 -21%Statin Users
HDL <40 34 42 23% Statin Users
Risk ratio 5.2 4.4 -15% Statin Users
3 OF 4
 BIOS LIFE CLINICAL STUDIES

EOT
No. Name Year Location Researchers N Design Intervention Outcomes Inclusion BL % % % vs Placebo
7 Utah #2 2006 Orem, UT Peter J.E. 39 Open 8 weeks
Verdegem label
Publications TC 208 185 -11.10%
Verdegem P, Duenas V, Duenas J, Burke E. LDL- and HLD-cholesterol TC >200 235 206 -12.30%
optimization using phytonutrient combination therapy: first line intervention and LDL 120 104 -13.30%
adjunct therapy to statins. in 1st Asian Preventive Cardiology & Cardiac LDL >130 154 120 -22.10%
Rehabilitation Conference. 2006. Hong Kong. LDL >160 173 134 -22.50%
HDL <40 25 30 20.00%
TG 210 181 -13.80%
TG >150 310 237 -23.50%

8 Texas 2006 Katy, TX Bobbi Horne, 34 Open 8 weeks

Isabel label
Martinez,
Peter J.E.
Verdegem

Publications TC 208 178 -14.20%

Martinez I, Horne B, Verdegem P. Lipid and glucose optimization using TC >200 245 195 -21.50%
phytonutrient combination therapy in diabetes. in 8th Annual Conference on LDL 127 104 -18.30%
Arteriosclerosis, Thrombosis and Vascular Biology. 2007.Chicago. LDL >160 197 141 -28.90%
HDL 46 48 3.50%
HDL <40 35 40 14.40%
TG 182 143 -21.30%
TG >150 242 163 -32.50%
GLU pre 162 134 -17.30%
GLU pre >175 218 155 -28.90%
HbA1c 7.2 6.6a -9.40%
HbA1c >8 9.2 7.8a -15.80%
a after 12
weeks

4 OF 4